Table: Brightpath Biotherapeutics -2023/24 parent results

BrightPath Biotherapeutics Co

10/05/2024 07:00

May 10 (Reuters)- 
          Brightpath Biotherapeutics Co., Ltd. 
          PARENT-ONLY FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended        Year to        NEXT   
              Mar 31, 2024    Mar 31, 2023    Mar 31, 2025      YEAR     
                 LATEST         YEAR-AGO         COMPANY       COMPANY   
                 RESULTS         RESULTS        FORECAST     H1 FORECAST 
  Sales           0 mln           5 mln           0 mln                  
               (-98.6 pct)     (-65.7 pct)     (-31.3 pct)               
  Operating     loss 1.16       loss 1.47     loss 925 mln               
  Recurring     loss 1.16       loss 1.47     loss 925 mln               
  Net           loss 1.17       loss 1.49     loss 927 mln               
  EPS        loss 18.21 yen  loss 24.90 yen  loss 13.08 yen              
  Ann Div          NIL             NIL             NIL                   
  -Q2 Div          NIL             NIL             NIL                   
  -Q4 Div          NIL             NIL             NIL                   
  
  NOTE - Brightpath Biotherapeutics Co., Ltd.. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T